Zyvox Related Published Studies
Well-designed clinical trials related to Zyvox (Linezolid)
Linezolid for patients with neutropenia: are bacteriostatic agents appropriate? [2009.05]
Affect of linezolid in ventilator-associated pneumonia caused by MRSA. [2009.03]
Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. [2009.01.15]
Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. [2008.12.01]
Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus. [2008.12]
Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. [2008.09]
Linezolid for the treatment of infections caused by Gram-positive pathogens in China. [2008.09]
Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. [2008.02]
Economic evaluation of linezolid versus teicoplanin for the treatment of infections caused by gram-positive microorganisms in Spain. [2007.08]
Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus. [2006.08]
Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections. [2006.06]
Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. [2006.03.01]
Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). [2005.12]
Absolute bioavailability and pharmacokinetics of linezolid in hospitalized patients given enteral feedings. [2005.09]
Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. [2005.06]
Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. [2005.04]
Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. [2005.03]
Linezolid eradicates MRSA better than vancomycin from surgical-site infections. [2004.12]
Effect of oral linezolid on the pressor response to intravenous tyramine. [2004.11]
Aqueous and vitreous penetration of linezolid (Zyvox) after oral administration. [2004.06]
An economic evaluation of a European cohort from a multinational trial of linezolid versus teicoplanin in serious Gram-positive bacterial infections: the importance of treatment setting in evaluating treatment effects. [2004.04]
Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections. [2004.04]
Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. [2004.02]
Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis. [2004.02]
Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. [2004.02]
Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. [2004.01.01]
Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. [2003.12.15]
Concentrations in plasma, urinary excretion, and bactericidal activity of linezolid (600 milligrams) versus those of ciprofloxacin (500 milligrams) in healthy volunteers receiving a single oral dose. [2003.12]
Cytokines in periradicular lesions: the effect of linezolid treatment. [2003.10]
Hematologic effects of linezolid in young children. [2003.09]
Linezolid for the treatment of complicated skin and skin structure infections in children. [2003.09]
Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant gram-positive bacterial pathogens. [2003.09]
Linezolid versus vancomycin in the treatment of known or suspected resistant gram-positive infections in neonates. [2003.09]
Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. [2003.08]
Hospital resource use and cost of treatment with linezolid versus teicoplanin for treatment of serious gram-positive bacterial infections among hospitalized patients from South America and Mexico: results from a multicenter trial. [2003.06]
Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. [2003.05]
Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. [2003.04]
Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. [2003.03]
Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. [2003.03]
Linezolid: in infants and children with severe Gram-positive infections. [2003]
Single- and multiple-dose pharmacokinetics of linezolid and co-amoxiclav in healthy human volunteers. [2002.11]
Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. [2002.06.01]
Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis. [2002.06]
Approaches to analysis of length of hospital stay related to antibiotic therapy in a randomized clinical trial: linezolid versus vancomycin for treatment of known or suspected methicillin-resistant Staphylococcus species infections. [2002.02]
Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. [2002]
[Comparison of linezolid and vancomycin in nosocomial pneumonia: results of the multicenter double-blind study] [2002]
Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C]linezolid to healthy human subjects. [2001.08]
Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr. [2001.05]
Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. [2001.05]
Linezolid absolute bioavailability and the effect of food on oral bioavailability. [2001.04]
Clinical trial results with linezolid, an oxazolidinone, in the treatment of soft tissue and postoperative gram-positive infections. [2001.03]
Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. [2001.03]
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. [2001.02.01]
Ecological effects of linezolid versus amoxicillin/clavulanic acid on the normal intestinal microflora. [2001]
Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections. [2000.12]
A pharmacokinetic evaluation of concomitant administration of linezolid and aztreonam. [1999.12]
Well-designed clinical trials possibly related to Zyvox (Linezolid)
Dalbavancin. [2008]
Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus. [2005.02]
Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis. [2004.04]
Other research related to Zyvox (Linezolid)
Pure red cell precursor toxicity by linezolid in a pediatric case. [2009.09]
Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. [2009.09]
Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem. [2009.08.01]
Long-term linezolid treatment in a young child with extensively drug-resistant tuberculosis. [2009.08]
Colonization of the tip of a thoracic catheter by Enterococcus faecalis resistant to vancomycin and linezolid. [2009.08]
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis. [2009.08]
Update on the safety of linezolid. [2009.07]
Linezolid-induced purpuric medication reaction. [2009.07]
Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid? [2009.07]
Elevated creatine phosphokinase levels associated with linezolid therapy. [2009.06.15]
Linezolid treatment for gram-positive infections: a retrospective comparison with teicoplanin. [2009.06]
Use of linezolid in critically ill patients admitted to intensive care units. [2009.06]
Rifampin and linezolid in the treatment of methicillin-resistant Staphylococcus aureus preseptal cellulitis. [2009.05]
Efficacy and tolerability of linezolid in chronic osteomyelitis and prosthetic joint infections: a case-control study. [2009.04]
Vascular graft infection by Staphylococcus aureus: efficacy of linezolid, teicoplanin and vancomycin systemic prophylaxis protocols in a rat model. [2009.03]
Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome. [2009.01]
Biliary penetration and pharmacodynamic exposure of linezolid in liver transplant patients. [2009.01]
[Linezolid for the treatment of newborns infected with vancomycin-resistant Enterococcus faecium] [2009.01]
A novel antibiotic, linezolid, reduces intraperitoneal adhesion formation in the rat uterine horn model. [2009]
Linezolid for the treatment of drug-resistant infections. [2008.12]
[Sideroblastic anemia after prolonged linezolid therapy] [2008.11]
Glycopeptide insensitive Staphylococcus aureus subdural empyema treated with linezolid and rifampicin. [2008.11]
Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. [2008.11]
Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis. [2008.09.11]
Successful treatment of vancomycin-resistant enterococcal ventriculitis in a pediatric patient with linezolid. [2008.09]
Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia due to a linezolid "tolerant" strain. [2008.09]
Efficacy of linezolid alone and in combination with rifampin in staphylococcal experimental foreign-body infection. [2008.09]
Early Microbiologic Response to Linezolid Versus Vancomycin in Ventilator-Associated Pneumonia (VAP) Due to Methicillin-Resistant Staphylococcus aureus (MRSA). [2008.08.21]
Reduction in rates of methicillin-resistant Staphylococcus aureus infection after introduction of quarterly linezolid-vancomycin cycling in a surgical intensive care unit. [2008.08]
Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis. [2008.08]
Linezolid for the treatment of infections caused by Gram-positive pathogens in China. [2008.07.15]
Case series report of a linezolid-containing regimen for extensively drug-resistant tuberculosis. [2008.07]
Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis. [2008.07]
Activities of clindamycin, daptomycin, doxycycline, linezolid, trimethoprim-sulfamethoxazole, and vancomycin against community-associated methicillin-resistant Staphylococcus aureus with inducible clindamycin resistance in murine thigh infection and in vitro pharmacodynamic models. [2008.06]
Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption. [2008.06]
[Linezolid therapy for the treatment of nocardial infection: report of a case and review of the literature] [2008.06]
Comparison of the Therapeutic Efficacy of Linezolid and Vancomycin and Correlation of Serum and Tissue Malondialdehyde and Myeloperoxidase in an Experimental Mediastinitis Model. [2008.05.06]
Linezolid for tympanostomy tube otorrhea caused by methicillin-resistant Staphylococcus aureus and multiple drug-resistant Streptococcus pneumoniae. [2008.05]
Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany. [2008.04.24]
Pharmacoeconomics of linezolid. [2008.04]
Linezolid lock prophylaxis of central venous catheter infection. [2008.04]
An outbreak of colonization with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unit. [2008.04]
|
